Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 10.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compens |
Stammdaten
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Unternehmen & Branche
| Name | Design Therapeutics, Inc. |
|---|---|
| Ticker | DSGN |
| CIK | 0001807120 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,03 Mrd. USD |
| Beta | 1,58 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -69,792,000 | -1.22 | 226,203,000 | 212,503,000 |
| 2025-09-30 | 10-Q | 0 | -16,997,000 | -0.30 | 211,770,000 | 199,720,000 |
| 2025-06-30 | 10-Q | 0 | -19,083,000 | -0.34 | 222,886,000 | 213,037,000 |
| 2025-03-31 | 10-Q | 0 | -17,715,000 | -0.31 | 237,475,000 | 227,919,000 |
| 2024-12-31 | 10-K | 0 | -49,588,000 | -0.88 | 252,093,000 | 242,097,000 |
| 2024-09-30 | 10-Q | -13,039,000 | -0.23 | 261,629,000 | 252,453,000 | |
| 2024-06-30 | 10-Q | -11,793,000 | -0.21 | 269,582,000 | 261,242,000 | |
| 2024-03-31 | 10-Q | -11,105,000 | -0.20 | 278,793,000 | 269,557,000 | |
| 2023-12-31 | 10-K | -66,862,000 | -1.19 | 289,643,000 | 277,687,000 | |
| 2023-09-30 | 10-Q | -15,789,000 | -0.28 | 299,869,000 | 284,957,000 | |
| 2023-06-30 | 10-Q | -19,937,000 | -0.36 | 311,630,000 | 296,795,000 | |
| 2023-03-31 | 10-Q | -19,294,000 | -0.35 | 324,743,000 | 312,818,000 | |
| 2022-12-31 | 10-K | -63,308,000 | -1.14 | 341,137,000 | 327,310,000 | |
| 2022-09-30 | 10-Q | -17,704,000 | -0.32 | 354,569,000 | 340,938,000 | |
| 2022-06-30 | 10-Q | -14,999,000 | -0.27 | 367,932,000 | 357,163,000 | |
| 2022-03-31 | 10-Q | -13,265,000 | -0.24 | 378,801,000 | 370,309,000 | |
| 2021-12-31 | 10-K | -35,533,000 | -0.77 | 390,557,000 | 382,130,000 | |
| 2021-09-30 | 10-Q | -11,318,000 | -0.21 | 400,353,000 | 391,564,000 | |
| 2021-06-30 | 10-Q | -7,636,000 | -0.14 | 405,146,000 | 401,601,000 | |
| 2021-03-31 | 10-Q | -5,514,000 | 411,854,000 | 408,006,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-13 | William Arsani | Director | Open Market Sale | -217,627 | 5.25 | -1,142,541.75 | -77,4% | |
| 2025-08-13 | William Arsani | Director | Open Market Sale | -345,000 | 5.25 | -1,811,250.00 | -122,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.